A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

Clinical trial NCT03588650 · COMPLETED

Trial details

NCT number: NCT03588650
Sponsor: Shanghai Henlius Biotech
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors

Start date: 2018-08-07
Primary completion: 2021-06-28
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.